Skip to main content

UCB Medicines: Clinical Studies and Scientific Research Publication

Publications

Filter
This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.

Select product(s):
Select topic(s):
Phase:

*Includes seizure clusters and acute or prolonged seizures

146 result(s)

phase 3

CIMZIA® (certolizumab pegol)

Rheumatoid Arthritis
View

Efficacy and safety of certolizumab pegol plus methotrexate in patients with rheumatoid arthritis: 3-year data from the RAPID 2 study. 

Smolen JS, van Vollenhoven RF, Kavanaugh A et al.  April 30, 2019
phase 1

BRIVIACT® (brivaracetam) CV

View

A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synpatic vesicle glycoprotein 2A binding in healthy volunteers

Sjoerd J Finnema, Samantha Rossano, Mika Naganawa et al.  March 29, 2019
phase 1

FINTEPLA® (fenfluramine)

Dravet Syndrome, Lennox-Gastaut Syndrome
View

A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects

Brooks Boyd, Steven Smith, Arnold Gammaitoni et al.  October 19, 2018
phase 3

CIMZIA® (certolizumab pegol)

Plaque Psoriasis
View

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study. 

Lebwohl M, Blauvelt A, Paul C et al.  April 14, 2018
phase 3

CIMZIA® (certolizumab pegol)

Plaque Psoriasis
View

Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from two phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). 

Gottlieb A, Blauvelt A, Diamant T et al.  April 13, 2018
phase 2

Plaque Psoriasis
View

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial

K.A. Papp, J. F. Merola, A. B. Gottlieb et al.  March 30, 2018
phase 2

BIMZELX® (bimekizumab-bkzx)

Plaque Psoriasis
View

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.

Krueger James, Feldman Steven, Umezawa Yoshinori et al.  March 30, 2018
phase 3

CIMZIA® (certolizumab pegol)

Psoriatic Arthritis
View

4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. 

van der Heijde D, Deodhar A, FitzGerald O et al.  March 14, 2018
phase 3

CIMZIA® (certolizumab pegol)

Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
View

Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. 

van der Heijde D, Baraliakos X, Hermann K-G et al.  January 17, 2018
phase 1

BIMZELX® (bimekizumab-bkzx)

Psoriatic Arthritis
View

Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation 

Glatt Sophie, Baeten Dominique, Terry Baker et al.  December 23, 2017